We are delighted to share that Celaid Therapeutics has been selected as a participant in the LabCentral “Next Phase Program”, launching in 2026, through the LabCentral Loop Program co-hosted by LabCentral and Shonan Health Innovation Park.
This program supports biotech startup companies by providing access to research infrastructure, expert mentoring, and various resources to accelerate business growth. We are truly honored that our technology, strategic vision, and team execution capabilities have been recognized through this selection.
We would like to express our sincere appreciation to the teams at LabCentral and Shonan Health Innovation Park. We will continue to advance the development of our Hematopoietic Stem Cell product (CLD-001) in the U.S. and further enhance our HSC platform technologies to deliver meaningful innovation in the field.
